Telix PharmaceuticalsTLX +6.02%50 Interest Coverage is 0.31 as of Dec. 2025, which is 92% below its 10-year median of 3.91. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $27.71 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 377 Biotechnology companies, Telix Pharmaceuticals ranks worse than 98.14% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Telix Pharmaceuticals's
Operating Income
for the
six
months ended in Dec. 2025 was $7.2 Mil. Telix Pharmaceuticals's Interest Expense for the
six
months ended in Dec. 2025 was $-23.0 Mil.
Telix Pharmaceuticals's interest coverage for the quarter that ended in Dec. 2025 was 0.31.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Telix Pharmaceuticals's Interest Coverage or its related term are showing as below:
TLX'
s Interest Coverage Range Over the Past 10 Years
Min: 0.45 Med: 3.91 Max: No Debt
Current: 0.45
TLX's Interest Coverage is ranked worse than 98.14% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs TLX: 0.45
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Telix Pharmaceuticals Interest Coverage Related Terms
Telix Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TLX vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (TLX) has a Interest Coverage of 0.31 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Telix Pharmaceuticals and its competitors. This is 92% below median its historical median of 3.91. Over the past decade, Telix Pharmaceuticals' Interest Coverage has ranged from 0.45 to 10,000.00. According to the industry distribution chart, Telix Pharmaceuticals ranks #370 out of 377 companies in the Biotechnology industry, placing it in the top 98.1%.
Is Telix Pharmaceuticals' Interest Coverage too high?
Telix Pharmaceuticals' current Interest Coverage of 0.31 is 92% below median its 10-year median of 3.91. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 10,000.00. The Biotechnology industry median Interest Coverage is 106.07. Telix Pharmaceuticals' value of 0.31 is 99.7% below this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #370 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #370 out of 377 companies for Interest Coverage. This places Telix Pharmaceuticals in the lower half of its industry. The industry median Interest Coverage is 106.07. Telix Pharmaceuticals' value of 0.31 is 99.7% below this benchmark. Historically, Telix Pharmaceuticals' own Interest Coverage has ranged from 0.45 to 10,000.00 over the past decade. While the company's 10-year median is 3.91 vs. the industry median of 106.07, Telix Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current Interest Coverage of 0.31 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current Interest Coverage is 0.31, which is 92% below median its own 10-year median of 3.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $27.71, compared to a current price of $10.83 — trading 60.9% below its estimated fair value. The current Interest Coverage is 0.31, which is 92% below median its 10-year median of 3.91 and 99.7% below the Biotechnology industry median of 106.07. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Interest Coverage is 0.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.83 is trading 60.9% below its estimated GF Value™ of $27.71.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
Interest Coverage: 0.31 (92% below median its 10-year median of 3.91)
GF Value™: $27.71 vs. price of $10.83 (60.9% below fair value)
Industry Position: 99.7% below the Biotechnology median (#370 of 377)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
